NARIMAN KONJKAVFARD: Open Payments
NPI 1619580032 · ELIZABETH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,419 in 76 payments from 10 companies in 2025. Trend: 2023 $230 · 2024 $1,141 · 2025 $1,419
Food & beverage: $1,419
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $440 |
| Teva Pharmaceuticals USA, Inc. | 12 | $208 |
| ABBVIE INC. | 13 | $199 |
| Otsuka America Pharmaceutical, Inc. | 11 | $164 |
| Janssen Pharmaceuticals, Inc | 7 | $124 |
| Neurocrine BioSciences, Inc. | 5 | $91 |
| Lundbeck LLC | 5 | $84 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $54 |
| E.R. Squibb & Sons, L.L.C. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
Products named: ARISTADA, VRAYLAR, LYBALVI, INVEGA SUSTENNA, UZEDY, REXULTI, ABILIFY ASIMTUFII, INGREZZA.
Industry payments across NJ — which companies pay providers there.
